Evidence map›Paper›PMID 32727735›Full record

ArticleCancer discovery2020

Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities.

Marcus R Kelly, Kaja Kostyrko, Kyuho Han, Nancie A Mooney, Edwin E Jeng, Kaitlyn Spees, Phuong T Dinh, Keene L Abbott, Dana M Gwinn, E Alejandro Sweet-Cordero and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Functional characterization of the 9q34.13 locus identifiesbioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. CRISPRingCancers · 2024
    Review
  14. Review
  15. Article
  16. Article
  17. Dynamic regulation of RAS and RAS signaling.The Biochemical journal · 2023
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Marcus R Kelly *Baxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, California.
Kaja Kostyrko *Division of Hematology and Oncology, Department of Pediatrics, University of California, San Francisco, San Francisco, California.ORCID https://orcid.org/0000-0002-2842-4089
Kyuho Han *Department of Genetics, Stanford University School of Medicine, Stanford, California.ORCID https://orcid.org/0000-0003-4259-8736
Nancie A MooneyBaxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, California.
Edwin E JengDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID https://orcid.org/0000-0003-2824-4763
Kaitlyn SpeesDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Phuong T DinhDivision of Hematology and Oncology, Department of Pediatrics, University of California, San Francisco, San Francisco, California.
Keene L AbbottBaxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, California.ORCID https://orcid.org/0000-0002-6166-704X
Dana M GwinnDivision of Hematology and Oncology, Department of Pediatrics, University of California, San Francisco, San Francisco, California.
E Alejandro Sweet-CorderoDivision of Hematology and Oncology, Department of Pediatrics, University of California, San Francisco, San Francisco, California. pjackson@stanford.edu bassik@stanford.edu Alejandro.Sweet-Cordero@ucsf.edu.
Michael C BassikDepartment of Genetics, Stanford University School of Medicine, Stanford, California. pjackson@stanford.edu bassik@stanford.edu Alejandro.Sweet-Cordero@ucsf.edu.
Peter K JacksonBaxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, California. pjackson@stanford.edu bassik@stanford.edu Alejandro.Sweet-Cordero@ucsf.edu.
Stanford University · USUniversity of California, San Francisco · USStanford Health Care · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancerU01CA199216 · NCI · STANFORD UNIVERSITY · PI BASSIK, MICHAEL C, JACKSON, PETER KENT · 2015 to 2019
$3.2M
NCI NIH HHS U01 CA199216
6 · The paper itself

Abstract

Activating mutations in RAS GTPases drive many cancers, but limited understanding of less-studied RAS interactors, and of the specific roles of different RAS interactor paralogs, continues to limit target discovery. We developed a multistage discovery and screening process to systematically identify genes conferring RAS-related susceptibilities in lung adenocarcinoma. Using affinity purification mass spectrometry, we generated a protein-protein interaction map of RAS interactors and pathway components containing hundreds of interactions. From this network, we constructed a CRISPR dual knockout library targeting 119 RAS-related genes that we screened for

Indexed as

HumansLung NeoplasmsProteomicsras Proteinsras Proteins

Identifiers

PMID32727735
PMCPMC7710624
OpenAlexW3045973649

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.